NCT00003190View on ClinicalTrials.gov

Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloid Leukemia

PHASE3CompletedINTERVENTIONAL
Enrollment

640

Participants

Timeline

Start Date

January 31, 1998

Primary Completion Date

August 31, 2002

Conditions
Adult Acute Megakaryoblastic Leukemia (M7)Adult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Monoblastic Leukemia (M5a)Adult Acute Monocytic Leukemia (M5b)Adult Acute Myeloblastic Leukemia With Maturation (M2)Adult Acute Myeloblastic Leukemia Without Maturation (M1)Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Adult Acute Myelomonocytic Leukemia (M4)Adult Erythroleukemia (M6a)Adult Pure Erythroid Leukemia (M6b)Untreated Adult Acute Myeloid Leukemia
Interventions
DRUG

cytarabine

Given IV

DRUG

daunorubicin hydrochloride

Given IV

DRUG

etoposide

Given IV

DRUG

valspodar

Given IV

Trial Locations (1)

60606

Cancer and Leukemia Group B, Chicago

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00003190 - Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloid Leukemia | Biotech Hunter | Biotech Hunter